{"id":"NCT02476175","sponsor":"CHU de Quebec-Universite Laval","briefTitle":"Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder","officialTitle":"Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04","primaryCompletion":"2016-04","completion":"2016-06","firstPosted":"2015-06-19","resultsPosted":"2018-04-24","lastUpdate":"2018-04-24"},"enrollment":35,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder","Urinary Incontinence"],"interventions":[{"type":"DRUG","name":"Mirabegron","otherNames":["Myrbetriq"]}],"arms":[{"label":"Add-on Mirabegron","type":"EXPERIMENTAL"}],"summary":"The objective is to evaluate the efficacy and safety of adding mirabegron to an antimuscarinic to treat urinary incontinence in children with Overactive Bladder that are refractory to antimuscarinics.","primaryOutcome":{"measure":"Response to Urinary Incontinence as a Composite Measure of Efficacy of add-on Mirabegron","timeFrame":"up to 52 weeks","effectByArm":[{"arm":"Add-on Mirabegron","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["Transcient constipation","Abdominal colic","Temporary blurred vision","Rhinitis"]}}